top of page

News & Events

FDA-clearance-510k.png

February 7, 2024

Corporis Medical achieves market approval in the USA for the Mediclose™ System, via a 510(k) pre-market submission to the FDA

After extensive review of Corporis Medical’s 510(k) pre-market submission, the FDA has granted its approval for the Mediclose™ System to enter the US market!

We are currently entertaining discussion with potential US distributors.

20231114_155956.jpg

November 14, 2023

Corporis Medical visits Medica and CompaMed

The Corporis Medical Team visited Medica and CompaMed last Tuesday, November 14, 2023. It was an interesting day filled with fruitful discussions and inspiring presentations. 

Vakkundig-gekeurd-audit.jpg

June 7, 2021

Corporis Medical passes a surveillence audit
EN ISO 13485:2016 

On June 7th, Corporis Medical passed the annual surveillance audit attesting to our high-quality management system in line with the ISO13485:2016 standard.

Naamloos-1.png

July 30, 2020

Corporis medical receives the kick-start fund from ESZL for the smallest blood pressure monitor.

Together with AIM and Medace, forces are joined to accelerate the production of the smallest blood pressure monitor, the laprixa.

In a Meeting

October 25, 2018

In-house ISO 13485:2016 Internal Auditor Training 

​Corporis Medical is organizing an in-house ISO 13485:2016 Internal Auditor Training at Brightlands Maastricht Health Campus on 8th and 9th of November 2018.

Medical form with stethoscope

December 19, 2017

Corporis medical raises 2 million for innovative surgical devices

In the Series A round, which was led by Chemelot Ventures and assisted by co-investors Limburg Business Development Fund (LBDF) and existing shareholder Inkef Capital, Corporis Medical has raised €2 million which the company intends to use the funding to obtain regulatory approval for the two devices.

national-cancer-institute-701-FJcjLAQ-unsplash.jpg

December 21, 2023

Corporis Medical successfully concludes First-in-Human study with the Mediclose™ System

Led by our CSO and founder Alexander Veenhof, Corporis Medical’s Mediclose™ System has been validated in patients in a multicenter First-in-Human clinical investigation. With this, we have demonstrated that the Mediclose™ System is safe for use and reduces port closure time significantly, compared to manual closure.

iso.png

October 20, 2023

Corporis Medical re-certification audit EN ISO 13486:2016

We are happy to announce that Corporis Medical is re-certified according to the ISO 13485:2016 standard. The annual surveillance audit by our notified body DEKRA, was passed with zero findings and no non-conformities.

shutterstock_1692360436.jpg

April 21, 2021

Corporis Medical presents at the Brightlands Webinar: Opportunities in the Netherlands and Catalonia

Klara Scupakova of Corporis Medical gave a Pitch about Corporis Medical and its products at the Brightlands Webinar on the opportunities in the health sector in the Netherlands and Catalonia.

mit-zuid.png

January 17, 2020

Corporis Medical receives MIT ZUID fund

The development of a new generation automatic trocar closure device, including clean room injection molding and scale-up, will be done together with Medanco Rubber & Plastic Solutions B.V. and is made possible by the European fund for regional development MIT ZUID. 

Naamloos-3.png

October 4, 2018

Corporis Medical, AIM BV and CSEM SA announce collaboration.

​An Eurostars grant was awarded for the consortium built between Corporis Medical, AIM BV and CSEM SA. The aim of this collaboration is to further develop the Perfusion Measurement technology towards a commercial device.

brightlands_campus_maastricht1.jpg

December 01, 2017

Move to Brightlands health campus

As of 1 December, Corporis medical will be based at the brightlands health campus at oxfordlaan 55, Maastricht. 

businessdeal.png

December 7, 2023

Corporis Medical closes €4M series B financing round

Corporis Medical completed an all equity financing round, including the conversion of existing convertible loans. The round was led by Unorthodox Ventures, a venture capital firm based in Austin, Texas, with participation from existing investors, including Brightlands Ventures Partners and LIOF.

Proceeds will be used to fund a Randomized Controlled Trial for Mediclose™, as well as clinical validation of the fully integrated Laprixa™ System. “We are pleased that Unorthodox Ventures and our current stakeholders have shown unwavering confidence in our products that improve outcomes of surgical interventions. This round of funding will allow us to take important steps necessary to enable a market launch” said John Marugg, Chief Executive Officer of Corporis Medical.

certificate_edited.png

November 30, 2021

Corporis Medical  awarded EIT Health Quality Label

EIT Health awards Corporis Medical's “Objective surgical wound healing indicator” with the Quality Label. Following the Business Plan 2022 Call Evaluation by an international panel of independent experts, the proposal was scored as a high-quality project proposal in a highly competitive evaluation process. This project is recommended by EIT Health for additional funding sources.

Office Work

September 14, 2020

Corporis Medical has obtained the EN ISO 13485:2016 certification

Corporis Medical has obtained the EN ISO 13485:2016 certification after the successful audit in June 2020 for the design, development, manufacturing and distribution of devices for minimally invasive procedures.

Naamloos-2.png

July 1, 2019

Corporis Medical receives OP-Zuid subsidy for innovative diagnostic device

Together with AIM and Medanco, Corporis Medical is joining forces to develop the smallest blood pressure meter for the diagnostic determination of the blood flow in tissue.

DZd0vx7UMAIKUwC.jpg

March 29, 2018

Company presentation at Limburg Unlimited

On March 28 and 29, Brightlands will be exhibiting together with LIOF and the Limburg Employers Association at Limburg Unlimited, the ultimate platform for showcasing the province’s many strengths.

bottom of page